Skip to main content
. 2021 Apr 3;17(5):1413–1427. doi: 10.7150/ijbs.58876

Figure 4.

Figure 4

The differentiated expression of LRRC4C in samples and correlation with survival and clinicopathological characteristics of COAD patients. (A) Survival analysis for COAD patients with different LRRC4C expression. Patients were labeled with high expression or low expression depending on the comparison with the median expression level. p = 0.0414, HR=1.52(1.02-2.28) by log-rank test. (B) Differentiated expression of LRRC4C in the mucinous adenocarcinoma and adenocarcinoma sample, p=0.0008, by student's test. (C) The correlation of LRRC4C expression with clinicopathological staging Characteristics, P=0.0255, by One-Way ANOVA test. (D) Distribution of LRRC4C in T classification. The p = 0.0030, by One-Way ANOVA test. (E) Distribution of LRRC4C in N classification. The p = 0.0037, by One-Way ANOVA test. (F) Distribution of LRRC4C in M classification. The p = 0.0030, by Student's test. (G, H); Kaplan-Meier survival analysis for colon cancer patients in GSE39582 grouped into high or low LRRC4C expression determined by the comparison with the median. P = 0.0233, HR=1.40(1.05-1.86), by log-rank test for overall survival; P = 0.3295, HR=1.17(0.85-1.63) by log-rank test for DFS.